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Abstract
Background: Little is known regarding the associations between high-molecular-weight (HMW-) adiponectin, leptin and
soluble leptin receptor (sOB-R) and metabolic syndrome (MetS) in Chinese. Also few studies elucidate the effects of
inflammation and body fat mass on the relations.
Methods: Plasma HMW-adiponectin, leptin and sOB-R were measured among 1055 Chinese men and women (35,54 yrs).
Whole body and trunk fat mass were determined by Dual-energy X-ray absorptiometry. MetS was defined by the updated
NCEP/ATPIII criterion for Asian-Americans.
Results: HMW-adiponectin was inversely associated with MetS in multivariate model including fat mass index (FMI),
inflammatory markers, leptin and sOB-R (OR in the highest quartile =0.30, 95%CI 0.18,0.50, P,.0001). Plasma sOB-R was
also inversely associated with MetS independent of body fatness and inflammatory markers, whereas the association was
somewhat attenuated after adjusting HMW-adiponectin (OR for the highest quartile =0.78, 95%CI 0.47,1.32, P=0.15). In
contrast, leptin was associated with increased odds of MetS independent of inflammatory markers, HMW-adiponectin, and
sOB-R (OR for the highest quartile =2.64, 95%CI 1.35,5.18, P=0.006), although further adjustment for FMI abolished this
association.
Conclusions: HMW-adiponectin exhibited strong inverse associations with MetS independent of body composition,
inflammation, leptin and sOB-R; while the associations of leptin and sOB-R were largely explained by fat mass or HMW-
adiponectin, respectively.
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Introduction
Adipose tissue is an endocrine organ playing a pivotal role in the
pathogenesis of metabolic diseases. Several adipose-derived
adipokines have been demonstrated as mediators linking obesity
to insulin resistance, dyslipidemia and inflammation [1]. Adipo-
nectin, one of the most abundant adipokines in circulation,
exhibits insulin-sensitizing, fat-burning and anti-inflammatory
properties [2,3]. Hypoadiponectinmia frequently appeared in
Individuals with obesity, metabolic syndrome (MetS) and type 2
diabetes [4,5]. However, there are at least 3 isomers of
adiponectin, i.e., trimer, hexamer and high-molecular-weight
(HMW-) multimer [2]. Accumulating evidence suggests that
HMW-adiponectin is the most physiologically active form related
to glucose tolerance [6], insulin sensitivity [7], central fat
distribution and multiple metabolic disorders [8]. Previous studies
also indicated that HMW-adiponectin could be a useful marker to
evaluate risk of MetS or type 2 diabetes in elderly Japanese [9],
Japanese-Americans [10] or Caucasian women [11].
Another major and well studied adipokine in blood stream is
leptin which could suppress food intake and stimulate energy
expenditure [12]. However, rather than leptin deficient, obese
persons often have hyperleptinemia specified as ‘‘selective leptin
resistance’’ associated with MetS, type 2 diabetes and cardiovas-
cular disease (CVD) [13,14]. Circulating leptin is either in a free
form which could trigger downstream signaling or in a binding
form with its soluble receptor (sOB-R). Recently, a large
prospective cohort reported a strong inverse association between
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[15]. However, data regarding the associations of leptin and sOB-
R and MetS, the important risk factor of diabetes and CVD, is
rather limited and inconsistent [14–19].
Adipokines dysregulation has been considered as one of the
major mechanisms mediating adverse effects of excess body fat on
metabolic abnormalities. However, most studies so far have used
BMI to evaluate adiposity and it remains unclear how fat mass or
fat distribution per se influences the associations between the
adipokines and metabolic disorders. Moreover, body composition
may also vary according to ethnical background. Compared to
Caucasians, Asians are more likely to have abdominal obesity
under ‘‘normal BMI’’ [20] and prone to type 2 diabetes at lower
BMI [21]. Meanwhile, accompanying rapid diet and lifestyle
transition, epidemic trend of metabolic diseases has become a
major public health problem in China [22], which is estimated to
have 92.4 million adults with diabetes and another 148.2 million
people with prediabetes [23]. Obviously, understanding the roles
of these adipokines and also their modifying factors could be
critical for metabolic disease control and prevention in countries
like China.
Therefore, our primary aim was to examine the associations of
plasma HMW-adiponectin, leptin and sOB-R with risk of MetS
and its components. Meanwhile, we also evaluated how these
associations were modified by BMI, inflammatory markers, body
fat mass or trunk fat percentage and other established risk factors
in 1055 middle-aged Chinese men and women.
Methods
Study design and subjects
The study population was non-institutionalized residents from
The Gut Microbiota and Obesity Study, a case-control study of
normal weight (18# BMI ,24.0 kg/m
2) and overweight/obesity
(BMI $24.0 kg/m
2) participants [22] aged from 35 to 54 years
living in Shanghai for at least 10 years. Detailed study design and
inclusion/exclusion criteria were described elsewhere [24]. Four
men with missing values for adipokines were excluded. The final
analytical sample comprised 557 overweight/obese and 498
normal-weight subjects. The protocol was approved by the
institutional review board of the Institute for nutritional sciences,
Shanghai Institutes for Biological Sciences, Chinese Academy of
Sciences. Written informed consents were obtained from all
participants.
Information of demographics, health status, diet and lifestyles
was collected using a standardized questionnaire during home
interview. Dietary intake was assessed with a modified food
frequency questionnaire used in the National Survey on the Status
of Nutrition and Health of the Chinese People in 2002 [25].
Smoking and drinking were defined as ‘‘yes’’ or ‘‘no’’. Family
history of chronic diseases was defined as one of the parents or
siblings having CVD, stroke or type 2 diabetes. Educational
attainment was categorized according to self-reported school
years. Levels of physical activity were calculated as a sum of
metabolic equivalent (MET)-minute/week score [26] and then
classified as low, moderate and high. Sleeping was assessed by
average daily sleep time.
All participants had a physical examination after overnight
fasting. Body weight, height, waist circumference, blood pressure
were measured according to a standardized protocol described
elsewhere [27]. A dual-energy X-ray absorptiometry scan (DEXA,
QDR-4500, Hologic, Waltham, MA, USA) was conducted in 956
(90.6%) individuals and no significant difference in characteristics
was found between those with and without DEXA. Values for total
fat mass, trunk fat mass and trunk mass (kg) were obtained by
using software built into the scanner (version 11.2.1) and daily
quality control was performed using phantom #12447 the same as
previous study [28].
Laboratory measurements
The blood processing procedure and assays for fasting plasma
glucose, insulin, triglycerides, HDL cholesterol (HDL-C), high-
sensitive C-reactive protein (hsCRP) and IL-6 were described in a
previous study [29].
HMW-adiponectin was assessed using an ELISA kit (Millipore,
St. Charles, MO, USA). Leptin and sOB-R were determined also
by ELISA (R&D Systems Inc., Minneapolis, MN, USA). The
average intra-assay and inter-assay coefficients of variation (CVs)
were ,10%.
Ascertainment of metabolic syndrome
Metabolic syndrome was defined according to the updated
National Cholesterol Education Program Adult Treatment Panel
III criteria for Asian-Americans [30], which includes at least three
of the following components: 1) waist circumferences $90 cm in
men or $80 cm in women; 2) triglycerides $1.7 mmol/L; 3)
HDL-C ,1.03 mmol/L in men or ,1.30 mmol/L in women; 4)
blood pressure $130/85 mmHg, or current use of anti-hyperten-
sive medications; 5) fasting plasma glucose $5.6 mmol/L.
Statistical analysis
Fat mass index (FMI) was calculated based upon DEXA data as
total fat mass (kg)/height (m)
2 [28]. Trunk fat percentage was the
ratio of trunk fat mass (kg) to total trunk mass (kg). Homeostasis
model assessment of insulin resistance (HOMA-IR) was computed
using updated homeostasis model assessment methods (http://
www.dtu.ox.ac.uk/).
All continuous variables were log-transformed to improve
normality. General linear model was applied for the comparisons
between non-MetS and MetS (Table S1). Spearman partial
correlation coefficients were estimated after adjustment for age,
sex and other covariates (Table 1). Because of gender differences in
the distributions of adipokines, sex-specific quartile cut-points were
used. Multivariate logistic regression models were used to estimate
the odds ratios, adjusting for age (continuous), sex, newly
diagnosed diabetes (fasting plasma glucose $7.0 mmol/L or 2-h
post load plasma glucose $11.1 mmol/L), smoke (past/current or
not), current alcohol use (yes or not), family history of chronic
diseases (yes or not), education (0,9, 10,12 or .12 years),
physical activity (low, moderate or high), sleep (,7, 7,9o r$9h /
d), total energy intake (kcal/d), BMI or FMI or trunk fat
percentage, hsCRP, IL-6 and adipokines (log-transformed,
continuous). All statistical analyses were performed using Stata
9.2 (Stata, College Station, TX, USA). Two-sided P,0.05 was
considered statistically significant.
Results
Individuals with MetS were older, and had higher BMI, waist
circumference, blood pressure, fasting glucose, insulin, HOMA-
IR, triglycerides, inflammatory markers (hsCRP and IL-6), fat
mass index and trunk fat percentage, but lower HDL-C.
Meanwhile, they also exhibited lower concentrations of HMW-
adiponectin and sOB-R, but greater leptin compared with those
without MetS (Table S1).
HMW-adiponectin was inversely associated with BMI (Table 1,
r=20.31) and FMI (r=20.27). Controlling for FMI, HMW-
adiponectin was still associated negatively with trunk fat
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(r=20.22), HOMA-IR (r=20.22), triglycerides (r=20.28) and
IL-6 (r=20.08), while positively with HDL-C (r=0.29) and sOB-
R (r=0.17). In comparison, sOB-R showed somewhat weaker
associations: r=20.13 with waist circumference, r=20.09 with
triglycerides, r=0.17 with HDL-C and no relation to trunk fat
percentage (r=20.05).
In contrast, leptin was strongly correlated with BMI (r=0.66)
and FMI (r=0.75). After adjustment for FMI, only the
correlations with insulin (r=0.13), HOMA-IR (r=0.13), triglyc-
erides (r=0.09), remained statistically significant.
Risk of metabolic syndrome
HMW-adiponectin and sOB-R decreased (Figure 1, A and C)
while leptin increased (Figure 1B) with an increased number of
MetS components in both men and women (all P,.0001).
In multivariate logistic regression analyses, both HMW-
adiponectin and sOB-R were negatively, whereas leptin was
positively, associated with the risk of MetS independent of BMI
and inflammatory markers (Table 2, Model 1 and 2). The odds
ratios (ORs) comparing the highest with the lowest quartile were
0.34 (95%CI 0.20,0.58, Ptrend,.0001) for HMW-adiponectin,
0.68 (95%CI 0.41,1.13, Ptrend=0.05) for sOB-R and 2.60
(95%CI 1.34,5.05, Ptrend=.005) for leptin. Further adjustments
of leptin and sOB-R showed little impact on the association
between HMW-adiponectin and MetS. Similarly, adjustment for
sOB-R and HMW-adiponectin did not affect the association
between leptin and MetS. However, the significant association
between sOB-R and MetS disappeared after HMW-adiponectin
was included in the Model 3 (Ptrend=0.15). Replacing BMI with
FMI (Model 4) did not substantially change the significant
associations for both HMW-adiponectin and sOB-R (ORs in the
highest quartile were 0.30, 95%CI 0.18,0.50, Ptrend,.0001 and
0.61, 95%CI 0.36,1.02, Ptrend=0.02, accordingly); but abolished
the significance between leptin and the risk of MetS (Ptrend=0.23).
With respect to individual components of MetS (Table 3),
HMW-adiponectin was strongly associated with a decreased risk of
hypertriglyceridemia (OR in the highest quartile =0.26, 95%CI
0.16,0.42, Ptrend,.0001) and low HDL-C (OR in the highest
quartile =0.22, 95%CI 0.14,0.35, Ptrend,.0001), while margin-
ally associated with central obesity (OR in the highest quartile
=0.49, 95%CI 0.25,0.97, Ptrend=0.06) in the FMI-adjusted
model. Furthermore, trunk fat percentage adjustment did not
affect these associations substantially (data not shown). Meanwhile,
sOB-R was negatively associated with abdominal fat (OR in the
highest quartile =0.36, 95%CI 0.18,0.73, Ptrend=0.002), high
triglycerides (OR in the highest quartile =0.64, 95%CI
0.40,1.01, Ptrend=0.02) and low HDL-C (OR in the highest
quartile =0.47, 95%CI 0.31,0.73, Ptrend,.0001). In contrast,
leptin was only positively associated with hypertriglyceridemia
after adjustment for FMI (OR in the highest quartile =2.90,
95%CI 1.46,5.77, Ptrend=0.006).
Stratified analyses
Considering the obesity case-control design of this study and to
explore how obesity, total fat mass and trunk fat percentage
influenced the observed relationships, we conducted BMI-
stratified analyses. In both normal-weight and overweight group,
HMW-adiponectin showed strong inverse associations with
modified MetS, regardless whether BMI, FMI or trunk fat
percentage was adjusted (Table S2, Model 1 to 3). However,
leptin was not significantly associated with modified MetS under
control of total or abdominal adiposity. A negative association
between sOB-R and modified MetS was observed in normal
weight individuals only (Model 1), and the significant association
disappeared following adjustments of FMI or trunk fat percentage
(Model 2 and 3). The results remained essentially the same and no
significant interaction was found in consequent subgroup analyses
according to gender, FMI, hsCRP and HOMA-IR (Table S3).
Discussion
Among 1055 middle-aged Chinese men and women, we
observed that reduced plasma HMW-adiponectin and sOB-R,
and elevated leptin level were significantly associated with an
increased risk of MetS and some of its components independent of
multiple confounders including BMI and inflammatory markers.
However, body fat mass or adipokines showed different modifying
effects on these associations. Unlike the association between
HMW-adiponectin and MetS which was unaffected by adjusting
for fat depots or other adipokines, the positive associations
between leptin and MetS were mainly explained by total fat
mass, while the associations between sOB-R and MetS were
largely influenced by HMW-adiponectin.
HMW-adiponectin and metabolic syndrome
Our study indicated that low plasma HMW-adiponectin was a
strong and independent risk factor related to MetS in Chinese
when diet, lifestyles, adiposity, inflammatory factors leptin and
sOB-R were extensively controlled. The inverse associations of
adiponectin with metabolic diseases and type 2 diabetes have been
well established [4,5]. However, most studies only measured total
adiponectin rather than its high-molecular-weight multimer (12–
18mer), which may be more biologically active than trimer and
Table 1. Spearman partial correlation coefficients with
metabolic parameters
1.
HMW-
adiponectin
(mg/mL)
Leptin
(ng/mL)
sOB-R
(ng/mL)
BMI (kg/m
2)
2, 3 20.31 0.66 20.31
FMI (kg/m
2)
2 20.27 0.75 20.31
Trunk fat percentage (%) 20.18 20.04
ns 20.05
ns
Waist circumference (cm) 20.19 20.02
ns 20.13
Systolic blood pressure (mm Hg) 20.06
ns 20.03
ns 0.09
Diastolic blood pressure (mm Hg) 20.02
ns 20.006
ns 0.06
ns
Fasting glucose (mmol/L) 20.03
ns 0.04
ns 0.04
ns
Insulin (mU) 20.22 0.13 20.16
HOMA-IR 20.22 0.13 20.15
Triglycerides (mmol/L) 20.28 0.09 20.09
HDL cholesterol (mmol/L) 0.29 0.01
ns 0.17
hsCRP (mg/L) 20.05
ns 0.03
ns 20.009
ns
IL-6 (pg/mL) 20.08 0.008
ns 20.11
HMW-Adiponectin (mg/mL) 1 - -
Leptin (ng/mL) 0.02
ns 1-
sOB-R (ng/mL) 0.17 20.002
ns 1
1Analyses were conducted in 956 participants. All coefficients were significant
unless indicated ‘‘ns’’. Adjusted for age, sex, diabetes, smoke, alcohol, family
history of chronic diseases, education, physical activity, sleep, total energy
intake and fat mass index (FMI).
2Adjusted all abovementioned variables except FMI.
3Analyses were conducted in 1055 participants.
doi:10.1371/journal.pone.0016818.t001
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HMW-adiponectin and MetS was sparse and most of them were
limited by small sample size and residual confounding. In one
relatively large-scale study, Tabar et al. [9] reported inverse
associations between HMW-adiponectin and MetS and its
components, except high blood pressure in middle-aged to elderly
Japanese. Likewise, our study also supported such associations in
Chinese population. On the other hand, we found that low HMW-
adiponectin concentration was only significantly associated with
high triglyceride and low HDL-C, but not with elevated glucose
and central obesity. This minor discrepancy could be due to the
different definitions for MetS between two studies. It is also
plausible that more confounders were controlled in our analyses.
One interesting observation in current study is that associations
between HMW-adiponectin and MetS were independent of
adiposity measured by BMI, FMI, or trunk fat percentage. In
the Nurses’ Health Study, Heidemann et al. reported that higher
HMW-adiponectin was associated with lower insulin and diabetes
Figure 1. Geometric means (95%CI) of concentrations of HMW-adiponectin (A), leptin (B) and soluble leptin receptor (sOB-R, C) in
individuals with 0 to 5 components of metabolic syndrome. Black bars = Men; white bars = Women. All P values were ,.0001.
doi:10.1371/journal.pone.0016818.g001
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data demonstrated that significant negative correlations between
HMW-adiponectin and insulin or HOMA-IR (both r=20.22)
were independent of FMI. Moreover, adjustment for IL-6 and
hsCRP had little effect on the association between HMW-
adiponectin and MetS (Table 2). The mechanism underlining
adiponectin regulation and signaling pathway is rather complex
and non-adipose factors might also be involved. Besides fat cells,
adiponectin could be secreted by skeletal muscle, cardiac
myocytes and endothelial cells as well [2]. Moreover, two
receptors, namely AdipoR1 and AdipoR2, operate closely with
AMPK or PPAR-a pathway to enhance glucose uptake and
utilization in muscle, promote lipid oxidation in liver, and
improve systemic insulin sensitivity [2,31]. In addition, insulin
resistance and inflammatory factors, hallmarks of MetS, are
proposed to down regulate adiponectin production [2]. Previous
small-scale infusion studies suggested that correlations of adipo-
nectin with insulin sensitivity were independent of BMI [32], total
adiposity measured by DEXA, visceral fat measured by magnetic
resonance imaging and intramyocellular lipid measured by
1H-
magnetic resonance spectroscopy [33]. Indeed, both enlarged size
and increased number of subcutaneous adipocytes could lead to
accumulation of fat in non-adipose tissue, such as skeletal muscle,
liver and heart. These ectopic fats are closely related to
hypoadiponectinemia and might modify its link with insulin
resistance [34]. Due to the limitation of DEXA method in current
study, it is not possible to exclude the effects of visceral adiposity,
intramyocellular or intrahepatic lipid content or adipocytes size by
adjustment of FMI, although BMI were already partitioned by fat
mass and fat free mass,respectively [35]. Collectively, data from
our study and others supported that HMW-adiponectin was an
important biomarker for MetS in addition to many established
risk factors.
Leptin, soluble leptin receptor and metabolic syndrome
In this study, we also found strong associations between leptin
and risk of MetS with adjusting BMI, inflammation and several
known confounders (Table 2, Model 1 to 3). Interestingly, in
contrast to the case of HMW-adiponectin, these associations could
be diminished by adjusting FMI (Table 2, Model 4 and Table 3).
Previously, data from a cohort study in Caucasian population
suggested that leptin could predict future MetS independent of
baseline BMI [14]. While leptin was associated with MetS risk in
older Chinese women, but not in men after adjustment for BMI
[36]. However, it was noteworthy that most existing studies
utilized BMI to evaluate adiposity status, containing both fat and
fat-free mass, which have different influences on metabolic
disorders [28]. As an adipose-derived hormone, leptin plays a
critical role in regulating energy homeostasis [13]. However, it is
still not clear whether leptin resistance is one of the causes or the
consequences of obesity, or the ‘‘vicious cycle’’ of them might be
the culprit of metabolic disorders. In this study, we provide direct
evidence highlighting the key role of fat mass in hyperleptinemia
associated metabolic abnormalities. Our finding might be
particularly important for Chinese who are characterized to have
more body fat under given BMI [20,21].
In addition to hyperleptinemia, our data revealed that reduced
soluble leptin receptor (sOB-R), another component of leptin
resistance, was significantly associated with an increased MetS risk
independent of fat mass. sOB-R, formed by cleaving the
ectodomain of membrane-anchored leptin receptors, represents
the major leptin binding fraction in blood [37]. It regulates the
available leptin pool and downstream signaling [38]. Few
epidemiological studies have simultaneously investigated the
associations of both plasma leptin and sOB-R with MetS. In a
study from Framingham third generation participants (n=362),
leptin and free leptin index (molar ratio of leptin and sOB-R) were
positively associated with severity of MetS after adjustment for age
and sex [16]. With larger sample size, we further adjusted for diet,
lifestyle, BMI/FMI, inflammatory markers and adipokines.
However, our data indicated that leptin and sOB-R had unique
properties and might reflect the different aspects of MetS. For
instance, sOB-R was negatively associated with central obesity,
elevated triglyceride and reduced HDL-C, whereas leptin was only
associated with hypertriglyceridemia in multivariate regression
including FMI (Table 3). Given the wide distribution in tissues
containing membrane leptin receptors, it is reasonable to speculate
that non-adipose mechanism(s) such as tissue specific effect might
also play a role in sOB-R regulation. On the other hand, leptin
was almost exclusively secreted by adipocytes, particularly
subcutaneous fat. Hypertriglyceridemia might result from the
limited capacity of adipose tissue to store excessive fat or up-
regulated hepatic triglyceride secretion and down-regulated
plasma triglyceride degradation [39,40]. However, adjustment
for HMW-adiponectin could abolish significance between sOB-R
and MetS but not that between leptin and MetS (Table 2, Model
3). Indeed, findings from the Nurses’ Health Study showed an
inverse association between sOB-R and diabetes independent of
BMI and HMW-adiponectin [15]. Kim et al. found if leptin-
deficient mice have over-expressed adiponectin would result in
Table 2. Odds ratio (95%CI) of metabolic syndrome
according to sex-specific quartile of HMW-adiponectin, leptin
and sOB-R.
Adipokines Q1 Q2 Q3 Q4
P for
trend
HMW-adiponectin
1
Model 1
2 1 0.66 (0.41, 1.04) 0.46 (0.29, 0.74) 0.34 (0.20, 0.56) ,.0001
Model 2
2 1 0.65 (0.41, 1.04) 0.46 (0.29, 0.74) 0.34 (0.20, 0.58) ,.0001
Model 3
2 1 0.64 (0.40, 1.02) 0.46 (0.29, 0.74) 0.35 (0.21, 0.59) ,.0001
Model 4
3 1 0.60 (0.37, 0.96) 0.49 (0.30, 0.79) 0.30 (0.18, 0.50) ,.0001
Leptin
1
Model 1
2 1 1.89 (1.07, 3.34) 2.76 (1.51, 5.01) 3.02 (1.57, 5.78) 0.0009
Model 2
2 1 1.84 (1.03, 3.28) 2.60 (1.41, 4.78) 2.60 (1.34, 5.05) 0.005
Model 3
2 1 1.86 (1.03, 3.36) 2.57 (1.39, 4.75) 2.64 (1.35, 5.18) 0.006
Model 4
3 1 1.44 (0.80, 2.59) 1.70 (0.92, 3.17) 1.59 (0.78, 3.24) 0.23
sOB-R
1
Model 1
2 1 0.92 (0.58, 1.44) 0.61 (0.38, 0.98) 0.59 (0.36, 0.97) 0.01
Model 2
2 1 0.99 (0.62, 1.57) 0.64 (0.40, 1.04) 0.68 (0.41, 1.13) 0.05
Model 3
2 1 1.07 (0.67, 1.71) 0.70 (0.43, 1.13) 0.78 (0.47, 1.32) 0.15
Model 4
3 1 0.82 (0.52, 1.32) 0.56 (0.34, 0.91) 0.61 (0.36, 1.02) 0.02
1Model 1: adjusted for age, sex, diabetes, smoke, alcohol, family history of
chronic diseases, education, physical activity, sleep, total energy intake and
log-transformed BMI.
Model 2: model 1+ inflammatory factors (hsCRP and IL-6).
Model 3: model 2+ other adipokines (leptin and sOB-R or HMW-adiponectin).
Model 4: adjusted for log-transformed FMI instead of BMI in Model 1.
2Quartiles of HMW-adiponectin (mg/mL) were ,1.08, 1.08–1.84, 1.84–3.16,
.3.16 for men and ,1.86, 1.86–3.15, 3.15–5.33, .5.33 for women. Quartiles of
leptin (ng/mL) were ,1.95, 1.95–3.22, 3.22–5.58, .5.58 for men and ,5.92,
5.92–9.64, 9.64–15.21, .15.21 for women. Quartiles of sOB-R (ng/mL) were
,15.16, 15.16–18.19, 18.19–22.15, .22.15 for men and ,15.54, 15.54–18.45,
18.45–21.82, .21.82 for women.
3Data were available for 956 participants.
doi:10.1371/journal.pone.0016818.t002
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profile [41]. Obviously, further studies are warranted to clarify
whether there are functional and/or signaling crosstalk among
adiponectin, leptin and its receptor (s).
Strengths and Limitations
This is the first study that systematically investigates the
associations of HMW-adiponectin, leptin, sOB-R, body fat mass
measured by DEXA, along with a wide range of inflammatory and
metabolic parameters with MetS and its features in a relatively
large population with both sexes. Meanwhile, we acknowledge
some limitations. Because of the cross-sectional nature, no causal
relationship could be established. Also, despite of the originally
obesity case-control design, we adapted a cross-sectional approach
in data analyses in order to enhance statistical power. Neverthe-
less, similar associations of HMW-adiponectin, leptin with MetS
were observed in both normal and overweight/obese individuals
as well as in further subgroup analyses. Obviously, our findings
need to be confirmed prospectively in different populations.
In conclusion, we found strong inverse associations between
HMW-adiponectin and MetS independent of adiposity, inflam-
matory statuses, leptin and sOB-R. Similar associations between
sOB-R and MetS were also evidenced, but were weak and
attenuated by HMW-adiponectin adjustment. In contrast, leptin
showed strong positive associations with the risk of MetS which
could be mainly explained by body fat mass. Overall, current
study provides more mechanistic insights into the linkage of
adipose tissue, adipokines and inflammation to metabolic
syndrome and also more evidences for detection of decreased
HMW-adiponectin and leptin resistance in clinical settings to
prevent metabolic disorders and future diabetic and cardiovascular
outcomes.
Supporting Information
Table S1 Characteristics of participants
1. Abbreviations:
MetS = metabolic syndrome, hsCRP = high sensitive C-reactive
protein, HMW-adiponectin = high-molecular-weight adiponectin,
sOB-R = soluble leptin receptor.
1 Data were Mean 6 SD or
Median (IQR) or Number (percentage).
2 Adjusted for age and sex.
3 Data were available for 956 participants.
(DOC)
Table S2 Odds ratio (95% CI) of modified metabolic
syndrome according to sex-specific tertile of HMW-
adiponectin, leptin and sOB-R in BMI-stratified analy-
ses
1.
1 Definition of metabolic syndrome was modified: having 2
or more components of metabolic syndrome without central
obesity. Tertiles were based on sex-specific levels in BMI-stratified
subgroup. NO. of cases/control were 160/338 in normal weight
group and 414/143 in overweight group.
2 Adjusted for the same
variables in Table 2. Model 1: including BMI; Model 2: including
FMI; Model 3: adjustment for log-transformed trunk fat
percentage.
3 Data were available for 956 participants. NO. of
cases/control were 147/307 in normal weight group and 369/133
in overweight group.
(DOC)
Table S3 Odds ratio (95% CI) of metabolic syndrome
according to sex-specific tertile of HMW-adiponectin,
leptin and sOB-R in subgroup analyses
1.
1 Tertiles were
based on sex-specific levels in each subgroup. Adjusted for the
same variables as Model 4 in Table 2, including FMI. Data were
available for 956 participants.
2 Median concentration of FMI was
5.87 for men and 7.79 for women. Definition of metabolic
syndrome was modified: having 2 or more components of
Table 3. Odds ratio (95%CI) of individual metabolic syndrome component according to sex-specific quartile of HMW-adiponectin,
leptin and sOB-R
1.
Adipokines Q1 Q2 Q3 Q4 P for Trend
2
HMW-adiponectin
Central obesity 1 0.65 (0.35, 1.21) 0.68 (0.35, 1.31) 0.49 (0.25, 0.97) 0.06
Hyperglycemia 1 0.93 (0.61, 1.41) 0.80 (0.53, 1.22) 0.88 (0.58, 1.35) 0.45
Elevated blood pressure 1 0.69 (0.46, 1.05) 0.99 (0.65, 1.50) 0.88 (0.57, 1.35) 0.96
Hypertriglyceridemia 1 0.68 (0.45, 1.03) 0.39 (0.25, 0.60) 0.26 (0.16, 0.42) ,.0001
Reduced HDL-C 1 0.78 (0.53, 1.13) 0.54 (0.36, 0.79) 0.22 (0.14, 0.35) ,.0001
Leptin
Central obesity 1 0.60 (0.30, 1.23) 0.84 (0.40, 1.76) 0.50 (0.20, 1.30) 0.44
Hyperglycemia 1 1.48 (0.97, 2.25) 1.74 (1.06, 2.86) 1.50 (0.83, 2.73) 0.15
Elevated blood pressure 1 0.97 (0.61, 1.53) 0.76 (0.45, 1.27) 0.83 (0.45, 1.53) 0.43
Hypertriglyceridemia 1 2.12 (1.21, 3.70) 2.76 (1.51, 5.05) 2.90 (1.46, 5.77) 0.006
Reduced HDL-C 1 0.96 (0.61, 1.50) 0.88 (0.53, 1.46) 0.90 (0.50, 1.61) 0.69
sOB-R
Central obesity 1 0.56 (0.29, 1.09) 0.34 (0.17, 0.66) 0.36 (0.18, 0.73) 0.002
Hyperglycemia 1 1.24 (0.82, 1.87) 0.88 (0.58, 1.33) 1.32 (0.86, 2.03) 0.47
Elevated blood pressure 1 0.75 (0.50, 1.14) 1.02 (0.67, 1.55) 1.05 (0.68, 1.62) 0.54
Hypertriglyceridemia 1 0.87 (0.57, 1.33) 0.65 (0.42, 1.01) 0.64 (0.40, 1.01) 0.02
Reduced HDL-C 1 0.88 (0.60, 1.28) 0.57 (0.38, 0.84) 0.47 (0.31, 0.73) ,.0001
1Number of cases: central obesity (496), hyperglycemia (616), elevated blood pressure (395), hypertriglyceridemia (305), reduced HDL-C (331).
2Adjusted for the same variables as Model 4 in Table 2, including FMI. Analyses were conducted in 956 participants.
doi:10.1371/journal.pone.0016818.t003
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FMI.
3 Median concentration of hsCRP was 0.87 mg/L.
4 Median
level of HOMA-IR was 1.08.
(DOC)
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